Beximco Pharmaceuticals (LSE:BXP), the AIM-listed manufacturer of generic drugs and active pharmaceutical ingredients, reported a 35.6% jump in profit after tax to BDT 4,794.2m (£29.3m) for the half year ended 31 December 2025, against BDT 3,535m (£23.8m) a year earlier.
Net revenue rose 15.8% to BDT 27,800.2m (£170.2m) from BDT 24,013.4m (£161.5m), with domestic sales up 15.6% to BDT 25,743.1m (£157.6m) and export sales advancing 17.5% to BDT 2,057.1m (£12.6m).
The profit margin expansion was the sharper story: revenue growth of roughly 16% produced profit growth of more than twice that rate, suggesting meaningful operating leverage across the period.
In the second quarter alone, net sales rose 13.9% to BDT 14,005.3m (£85.7m), with profit after tax up 29.8% to BDT 2,392.9m (£14.6m), compared with BDT 1,843.1m (£12.4m) in the prior-year second quarter.
Total equity on the balance sheet stood at BDT 61,850.2m at 31 December 2025, up from BDT 57,084.6m at 30 June 2025, with retained earnings rising to BDT 44,962.7m from BDT 40,239.9m over the same period.
The results are unaudited and cover the six months to 31 December 2025.
